A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

Last updated: February 3, 2024
Sponsor: Zydus Lifesciences Limited
Overall Status: Active - Recruiting

Phase

4

Condition

Diabetes Mellitus, Type 2

Obesity

Diabetes Mellitus Types I And Ii

Treatment

Saroglitazar

Clinical Study ID

NCT05872269
SARO.21.003
  • Ages 18-80
  • All Genders

Study Summary

A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male and female patients aged ≥18 years
  2. Patients who have been prescribed Saroglitazar for NAFLD will be included in thisPhase 4 study (patients who use Saroglitazar for the first time)
  3. Patients able to and willing to provide written informed consent and comply with therequirements of the study protocol .
  4. Patients with a prior documented diagnosis of NAFLD based on the AASLD criteria. NAFLDis defined either by previous histology or clinical imaging in individuals who consumelittle or no alcohol and do not have a cause for secondary hepatic steatosis oranother cause of chronic liver disease. In addition, patients must have one of thefollowing criteria to indicate ongoing NAFLD at screening:
  5. Liver stiffness through transient elastography, an LSM ≥8 kPa OR
  6. Serum ALT ≥45 U/L

Exclusion

Exclusion Criteria:

  1. Consumption of alcohol for at least 90 consecutive days in last one year: >2 units ofalcohol per day (>14 units per week) for males and >1 unit of alcohol per day (>7units per week) for females. Note: 1 unit = 360 mL of beer, or 120 mL of wine, or 30mL of spirits/hard liquor
  2. History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis,cholestatic and metabolic liver diseases) and haemochromatosis.
  3. Patient has known documented cirrhosis, either based on clinical criteria or liverhistology or imaging.
  4. Contraindications to Saroglitazar or any disease conditions affecting the ability toevaluate the effects of Saroglitazar.
  5. History or other evidences of severe illness or any other conditions that would makepatient, in the opinion of the investigator, unsuitable for the study.
  6. Any previous history of ascites, hepatic encephalopathy, oesophageal varices oradmission/emergency department visit for hepatic decompensation.
  7. Women of child bearing potential: inability or unwillingness to practice contraceptionfor the duration of the study.
  8. Pregnant or breast feeding females

Study Design

Total Participants: 1500
Treatment Group(s): 1
Primary Treatment: Saroglitazar
Phase: 4
Study Start date:
July 20, 2023
Estimated Completion Date:
June 10, 2025

Study Description

The study is being planned to evaluate long term safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD).

Total 1500 male and female patients with NAFLD with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome).

Connect with a study center

  • Gastroplus Digestive Disease Centre

    Ahmedabad,
    India

    Active - Recruiting

  • Mission GastroHospital

    Ahmedabad,
    India

    Active - Recruiting

  • Artemis Hospital

    Gurgaon,
    India

    Active - Recruiting

  • Medanta- TheMedicity

    Gurgaon,
    India

    Active - Recruiting

  • Malla ReddyNarayanaMultispecialtyHospital

    Hyderabad,
    India

    Active - Recruiting

  • Osmania GeneralHospital

    Hyderabad,
    India

    Active - Recruiting

  • Yashoda Hospitals

    Hyderabad,
    India

    Active - Recruiting

  • CARE CHL -Hospitals (Unit ofConvenient HospitalLtd.

    Indore,
    India

    Active - Recruiting

  • S R Kalla MemorialGastro and GenralHospital

    Jaipur,
    India

    Active - Recruiting

  • AIIMS

    Khorda,
    India

    Active - Recruiting

  • Medanta Hospital

    Lucknow,
    India

    Active - Recruiting

  • Dayanand MedicalCollege & Hospital

    Ludhiāna,
    India

    Active - Recruiting

  • Neurociti Hospital

    Ludhiāna,
    India

    Active - Recruiting

  • TNMC & BYL NairCh. Hospital

    Mumbai,
    India

    Active - Recruiting

  • Shree Siddhivinayak Maternity & Nursing Home

    Nashik,
    India

    Active - Recruiting

  • Sir GangaramHospital

    New Delhi,
    India

    Active - Recruiting

  • Alchemist Hospital

    Panchkula,
    India

    Active - Recruiting

  • Fortis Hospital

    Rupnagar,
    India

    Active - Recruiting

  • BAPS Pramukh Swami Hospital

    Sūrat,
    India

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.